This preview shows page 1. Sign up to view the full content.
Unformatted text preview: g treatment
Emerging Beta-interferon blocks expression of MHC molecules
which are involved in presentation of self-antigens
(myelin) to T cells. FDA approved.
(myelin) Direct blocking of the MHC molecules that present selfantigens using molecules with high affinity to the MHC
binding Monoclonal antibodies that bind to tumor necrosis factor
and clear this cytokine from circulation. A single dose
can suppress the autoimmune response for 5 to 10
weeks. Blocking of T cell interactions, for example, with
endothelial cell receptors.
endothelial Vaccinate individuals against their own self-reactive T
cells. Case Study:
Lupus Afflicts an estimated 1.4 million Americans May disrupt almost any part of the body:
skin, joints, kidneys, heart, lungs, blood
vessels and brain.
vessels The immune system produces autoantibodies to a surprising variety of
molecules ranging from cellular surface
targets to targets inside cells and even to
DNA. Classic Symptoms
Classic A rash, often butterflyshaped, over the cheeks Reaction to sunlight in
which a skin rash arises
or Kidney disorder Presence of antinuclear
autoantibodies The cause
The Production of large amounts of very
diverse self attacking antibodies
diverse The auto-antibodies recognize selfantigens and generate immune complexes
antigens The immune complexes can recruit
complement molecules, which can harm
tissue The complexes also elicit an inflammatory
response Where are the auto-antibodies
coming Patients with lupus have excessive rate of
apoptosis in c...
View Full Document
This note was uploaded on 05/15/2012 for the course BME 365S taught by Professor Sokolov during the Spring '10 term at University of Texas at Austin.
- Spring '10